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Abstract
Background: Di-(2-ethylhexyl)-phthalate (DEHP) is a commonly used plasticizer in polyvinylchloride (PVC)
formulations and a potentially non-genotoxic carcinogen. The aim of this study was to identify genes whose level
of expression is altered by DEHP by using a global wide-genome approach in Syrian hamster embryo (SHE) cells, a
model similar to human cells regarding their responses to this type of carcinogen. With mRNA Differential Display
(DD), we analysed the transcriptional regulation of SHE cells exposed to 0, 12.5, 25 and 50 μM of DEHP for 24 hrs,
conditions which induced neoplastic transformation of these cells. A real-time quantitative polymerase chain
reaction (qPCR) was used to confirm differential expression of genes identified by DD.
Results: Gene expression profiling showed 178 differentially-expressed fragments corresponding to 122 genes after
tblastx comparisons, 79 up-regulated and 43 down-regulated. The genes of interest were involved in many
biological pathways, including signal transduction, regulation of the cytoskeleton, xenobiotic metabolism,
apoptosis, lipidogenesis, protein conformation, transport and cell cycle. We then focused particularly on genes
involved in the regulation of the cytoskeleton, one of the processes occurring during carcinogenesis and in the
early steps of neoplastic transformation. Twenty one cytoskeleton-related genes were studied by qPCR. The down-
regulated genes were involved in focal adhesion or cell junction. The up-regulated genes were involved in the
regulation of the actin cytoskeleton and this would suggest a role of cellular plasticity in the mechanism of
chemical carcinogenesis. The gene expression changes identified in the present study were PPAR-independent.
Conclusion: This study identified a set of genes whose expression is altered by DEHP exposure in mammalian
embryo cells. This is the first study that elucidates the genomic changes of DEHP involved in the organization of
the cytoskeleton. The latter genes may be candidates as biomarkers predictive of early events in the multistep
carcinogenic process.
Background
Di-(2-ethylhexyl)-phthalate (DEHP) is a commonly used
plasticizer in polyvinylchloride (PVC) formulations
which have a number of applications, especially in food
packaging, medical devices or cosmetics. Phthalates are
not chemically bound to PVC and can migrate from
PVC-containing products to the environment, resulting
in significant environmental contamination and human
exposure [1,2].
DEHP experiments have revealed toxicities including
carcinogenesis and endocrine-disrupting effects, but no
genotoxicity has been recorded [3]. DEHP is capable of
disturbing the reproductive process by mimicking or
antagonizing steroid hormone action [4] and its effects
on testosterone, luteinizing hormone or estrogen-like
activity have been reported [5,6]. DEHP has been shown
to decrease free testosterone levels in humans after
occupational exposure [7] and thyroid hormone levels in
adult men otherwise exposed [8].
* Correspondence: yann.landkocz@univ-metz.fr
1CNRS UMR7146, Laboratoire I.E.B.E., Rue General Delestraint, 57070 Metz,
France
Full list of author information is available at the end of the article
Landkocz et al. BMC Genomics 2011, 12:524
http://www.biomedcentral.com/1471-2164/12/524
© 2011 Landkocz et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.DEHP has been classified as a peroxisomal proliferator
and as a non-genotoxic carcinogen in animals [9].
Experimental studies using rodents and in vitro assays
showed that DEHP and its active metabolite MEHP
(mono-(2-ethylhexyl)-phthalate) can interact with
nuclear receptors like PPARa [10] or PPARg [11]. Oxi-
dative stress, as a result of peroxisome proliferation, and
DNA damage have been described in the human pros-
tate adenocarcinoma cell line LNCaP [12,13] and the
mouse Leydig tumor cell line MA-10 [14] exposed to
high concentrations of DEHP (3 mM). Peroxisome pro-
liferation is one of the mechanisms that produce liver
tumors in rats or mice, but this mechanism was not
judged to be relevant in humans [15]. The liver is not
t h es o l et a r g e tf o rD E H Pc a r c inogenicity: testicular
tumors [16] and pancreatic acinar adenomas have also
been reported [17]. Other studies have pointed out that
peroxisome proliferation is not a necessarily pathway in
the carcinogenicity of DEHP [18] and more liver tumors
occurred in PPARa-null mice than in wild type animals
[19]. Transcriptional changes independent of PPARa
were also found in rats and mice exposed to DEHP [20].
Several non-PPARa mechanisms were addressed: activa-
tion of p38 mitogen-activated protein kinase not
involved in peroxisome proliferations [21]; stimulation
of growth regulatory pathways, mitogen-activated pro-
tein kinase, extracellular signal-regulated kinase and p38
phosphorylation [22]. Other mechanisms related to non-
genotoxic carcinogenicity, like inhibition of gap junc-
tional intercellular communication [23] or inhibition of
apoptosis, were reported. Apoptosis was shown to be
suppressed by DEHP through different pathways. An
interference with the cytokine TGF-b1( t r a n s f o r m i n g
growth factor-b1) [24] or with TNF-a (tumor necrosis
factor-a) has been described [25]. An increased level of
Bcl-2 and negative regulation of c-Myc expression has
been related to inhibition of apoptosis in Syrian hamster
embryo cells treated with 50 μM of DEHP [26].
Several authors have demonstrated that DEHP and its
active metabolite MEHP induce morphological transfor-
mation of SHE cells [27-29], indicating the carcinogenic
potency of the two chemicals. Although phthalate toxi-
city has been extensively investigated over the past 10
years, the mechanisms of DEHP carcinogenicity have
not been elucidated. It was recently stated by the Inter-
national Agency for Research on Cancer (IARC) that
PPAR-independent mechanisms of DEHP carcinogenesis
are necessary to be studied [http://monographs.iarc.fr/
ENG/Publications/techrep42/TR42-18.pdf].
The choice of cellular models and methodologies is
critical to the study of the phenomenon of carcinogen-
esis. Syrian hamster embryo cells are a relevant model
for mechanistic studies of chemical carcinogenicity. SHE
cells, unlike mouse and rat cells, are less responsive to
peroxisomal proliferation and, in this respect, more
similar to human cells. SHE cells are normal, diploid,
genetically stable and primary cells which are metaboli-
cally competent for procarcinogen activation. Therefore
they are used to study mechanisms of in vitro carcino-
genesis [30]. SHE cells are obtained from embryos after
removal of the differentiated tissues, and the population
is mainly composed of epithelial and fibroblastic cells
[31]. SHE cells from colonies having been morphologi-
cally transformed after short exposure to chemical carci-
nogens induced tumours when transplanted back into
hamsters [32]. This validated the model and the cell
transformation criteria for in vitro carcinogenicity.
Recently, the SHE cell transformation assay has been
recommended by OECD in 2007 as in vitro method of
screening chemical carcinogens on the basis of its per-
formances to detect non-genotoxic as well as genotoxic
carcinogens [http://www.oecd.org/dataoecd/56/5/
37863750.pdf].
The aim of this work was to use a global transcrip-
tomic approach to understand the molecular mechan-
isms of cell transformation induced by DEHP in SHE
cells. The objectives were to identify changes in gene
expression occurring in the early steps of cell transfor-
mation as well as pathway disturbances that may trigger
a carcinogenic process. A characterization of the genes
expressed in SHE cells at DEHP concentrations inducing
cell transformation may give information on PPAR-inde-
pendent mechanisms and alternative pathways of DEHP
carcinogenicity. The transcriptomic changes induced by
DEHP in SHE cells were analyzed in the first hours of
exposure. We focused secondly on changes of cytoskele-
ton-related genes underlying morphological transforma-
tion in SHE cells. Indeed, cell transformation is
expressed by the alteration of cell morphology, a disor-
ganized pattern of colony growth and the acquisition of
anchorage-independent growth which is predictive of
their ability to induce tumors when injected into syn-
genic animals [33]. Despite the central role of the actin
cytoskeleton throughout the life cycle, little is known
about the gene expression changes involved in deregula-
tion of its dynamic in the first stages of tumorigenesis.
Cytoskeleton defects in relation to cancer have been
mostly studied in the late stages of cell invasion and
metastasis.
Differential Display was chosen to identify differen-
tially-expressed genes in SHE cells and to explore the
entire genome. The mRNA differential display described
by Liang and Pardee [34] is a powerful approach for
transcriptomic analysis. This methodology has become
popular as a tool for non-model organisms because of
lack of requirement of previous genomic information
about the species of interest. As the genome of hamster
is partly characterized so far, Differential Display
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dent effects in SHE cells. We applied the current metho-
dology that uses a combination of 3 “anchored” oligo-dT
primers (to divide the cDNA population in 3 subsets)
and 80 “arbitrary” primers of 13-mers. The 240 primer
combination allowed us to obtain a level of 95% gene
coverage [35].
DD was applied to cells exposed for 24 hrs to DEHP.
Genes corresponding to differentially-expressed frag-
ments were characterized. Differential Display allowed
us to screen a set of differentially-expressed fragments
in treated cells, among which 122 genes were identified
as targeted by a 24 hr-DEHP exposure. These genes
were involved in such functions as transcription signal-
ling pathways, cytoskeleton regulation, apoptosis, meta-
bolism. As Differential Display is a semi-quantitative
method, the expression changes of the genes we were
interested in, were checked by qPCR using hamster spe-
cific primers. qPCR was applied to RNAs not only from
24 hr-treated cells, but also from cells treated for 5 hrs
in order to study the cell response in the meantime. We
particularly focused on changes of cytoskeleton-related
genes underlying morphological transformation in SHE
cells. The objective was to explain from a mechanistic
point of view the gene expression changes after DEHP
e x p o s u r e .T ot h eb e s to fo u rk n o w l e d g e ,t h i se x e r c i s e
has never been done previously.
Results
Identification of DEHP-responsive genes using Differential
Display
The Differential Display technique was used to identify
genes differentially expressed in SHE cells, after 24 hrs
of treatment with DEHP. An illustration of differen-
tially-expressed fragments is given in Figure 1 which
s h o w sg e l so b t a i n e da f t e rt h eD Dp r o t o c o la n dh i g h -
lights fragments regulated more than 2-fold by DEHP.
Using 3 anchored primers and 80 arbitrary primers, 178
differentially expressed fragments were identified (115
up-regulated and 63 down-regulated). Among these
transcripts, 141 (79%) showed homology to known
genes in the RefSeq database (mouse or human) of Gen-
bank, while 37 (21%) had no homology or homology to
hypothetical proteins. The sequences of the fragments
obtained by DD have been deposited in the Genbank
dbEST database (LIBEST_027390 Syrian Hamster
Embryo cells library). These 141 fragments corre-
sponded to 122 genes that are listed in table 1 with
their accession numbers and the tblastx expected (the
threshold for tblastx comparison was p ≤ 0.001). These
genes were classed according to 8 biological functions
with reference to the GO process database. These func-
tions included signal transduction and transcription,
cytoskeleton regulation, xenobiotic metabolism,
apoptosis, lipidogenesis, protein conformation or trans-
port and cell cycle. The regulation of the cytoskeleton
was one of the most impacted pathways. Indeed, 21
genes involved in this function were differentially
expressed after DEHP exposure. Ten genes were up-
regulated, and 11 were down-regulated.
Transcription and signal transduction is another biolo-
gical process targeted by DEHP treatment. We found 22
up-regulated genes, among which 3 were up-regulated
more than 10-fold (rab1b, a Ras oncogen family mem-
ber, Homeobox 1 and Forkhead P1). Heat- shock
response related genes (hsp90, hsp70 and hsph1) and the
Figure 1 Representative Differential Display. This figure shows
results obtained with control (C), vehicle control (VC) and DEHP-
treated (12.5, 25 and 50 μM) SHE cells mRNA, after 24 hrs of
exposure. Arrows indicate fragments regulated more than 2-fold
and used for the next step of analysis. The DD fragments were
generated using the A-anchored primer (H-dT+A) combined with
the arbitrary primer H-AP37 (lane a) or H-AP52 (lane b) and the G-
anchored primer (H-dt+G) combined with the arbitrary primer H-
AP40 (lane c). After characterization by sequencing, we obtained the
following genes: a1:Rlp37a/a2:Rlp27a/a3:Col1a1/b1:Cttnbip1/b2:
Enah/c1: Coro1C.
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function, according to GO process
Id Official symbol Gene Name Accession Nr Tblastx expect Effect of DEHP
1-Transcription and Signal Transduction
A0601 Hsp90 Heat shock protein 90 kDa protein NM_010478 9E-25 +
A0602 Hsp70 Heat shock protein 70 kDa protein NM_005346 1E-24 +
A3201 Cebpd CCAAT/enhancer binding protein delta NM_005195 9E-10 -
A4102 Ncbp2 nuclear cap binding protein subunit 2 NM_007362 6E-21 +
A5101 Mettl5 methyltransferase like 5 NM_029280 7E-10 +
A5102 Ogt O-linked N-acetylglucosamine transferase NM_181672 5E-28 +
A6101
A6102
Nr1i2 nuclear receptor subfamily 1I2 NM_003889 1E-158
3E-74
+
A6302 Mapk15 mitogen-activated protein kinase 15 NM_177922 3E-16 +
A6801 Rab1b member of RAS oncogene family NM_030981 1E-22 ++
A7502 Mdb1 methyl-CpG binding domain protein 1 NM_013594 2E-16 –
C0602 Gper G protein-coupled estrogen receptor 1 NM_001098201 6E-68 +
C1001 Hmbox1 Homeobox 1 NM_024567 2E-32 ++
C1002 Mapk3 mitogen-activated protein kinase 3 NM_001109891 9E-60 -
C1301 Usp3 Ubiquitin peptidase 3 NM_006537 9E-34 +
C1401 Psmc5 26S protease regulatory subunit ATPase 5 NM_002805 2E-23 -
C4601 Hsph1 heat shock 105kDa/110kDa protein NM_006644 5E-07 +
C4802 Irf2 interferon regulatory factor 2 NM_008391 8E-19 +
C7101 Lmo4 LIM domain only 4 NM_006769 7E-09 +
G0301 Smarcc1 SWI/SNF related actin dependent regulator of chromatin NM_003074 3E-20 -
G1001 Chd4 ATP dependant hélicase 4 NM_001273 1E-45 -
G1504 Foxp1 Forkhead box P1 NM_032682 3E-50 ++
G1701 Creb3l1 cAMP responsive element binding protein 3-like 1 NM_052854 8E-19 +
G1902 Pbrm Polybromo domain NM_001081251 8E-49 +
G3301 Rxfp2 relaxin/insulin-like family peptide receptor 2 NM_130806 1E-24 +
G3501 Akap5 A kinase anchor protein 5 NM_004857 1E-05 +
G3801
G7001
Eif1 eukaryotic translation initiation factor 1 NM_005801 3E-42
1E-15
+
G4801 Spry3 sprouty homolog 3 NM_005840 0.0002 +
G6001 Foxa3 forkhead box A3 NM_008260 9E-17 -
G6201 Mett5d1 methyltransferase 5 containing 1 NM_029790 0.0038 +
2-Regulation of cytoskeleton
A0201 Cttnbp2 Cortactin binding protein 2 NM_030249 0.0001 +
A1901 Snx6 sorting nexin 6 NM_021249 8E-10 -
A2401 Lrrc8a leucine rich repeat containing 8A NM_177725 5E-32 -
A3501
A3502
C3501
G3502
G3503
Actb beta-actin NM_007393 3E-51
1E-106
2E-21
7E-114
3E-48
+
A3702 Col1a1 collagen, type I, alpha 1 NM_000088 1E-21 +
A3801 Nrp2 neuropilin 2 NM_0010774 1E-22 -
A5201 Ctnnbip1 catenin beta interacting protein 1 NM_020248 0.0008 -
A5202 Enah enabled homolog NM_008680 2E-09 -
A5402 Kif23 kinesin family member 23 NM_024245.4 1E-25 ++
A7501 Cdh3 cadherin 3 NM_007665 0.0007 -
C4502 Nid2 nidogen 2 NM_008695 0.006 -
C6603
C6604
C6605
Crip1 cysteine-rich protein 1 NM_007763 1E-31
9E-08
3E-61
+
G0601 Thy1 Thy-1 cell surface antigen NM_009382.3 0.001 -
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tion, according to GO process (Continued)
G0801 Calml3 calmodulin-like 3 NM_027416.3 0.0004 +
G1102 Flrt2 fibronectin leucine rich transmembrane protein 2 NM_201518 2E-08 -
G1301 Has2 hyaluronan synthase 2 NM_008216 8E-18 -
G1901 Plekha5 Pleckstrin homology domain A5 NM_019012 3E-06 +
G2301 Thbs1 thrombospondin 1 NM_011580 3E-20 -
G4001 Coro1C coronin, actin binding protein NM_014325 4E-07 +
G4802 Tubb2b Tubulin beta NM_023716 0.0001 +
G6901 Dclk1 doublecortin-like kinase 1 NM_019978 1E-06 +
3-Xenobiotic metabolism
A0901 Cyp2e1 Cytochrome P450 2e1 NM_021282 3E-44 +
A2901 Ephx1 Epoxide Hydrolase 1 NM_000120 4E-21 +
A5701 Gstp1 glutathione S-transferase, pi 1 NM_000852 1E-24 +
A6601 Gstt1 glutathione S-transferase, theta 1 NM_008185 1E-44 -
C0101
C1501
G1502
Txnrd1 Thioredoxin reductase 1 NM_001042523 1E-20
1E-14
3E-79
+
C2901 Cyp1b1 Cytochrome P450 1b1 NM_009994 0.0 +
C3101 Gstm5 glutathione S-transferase, mu 5 NM_010360 4E-51 -
C3701 Tnfa tumor necrosis factor-alpha NM_011659 0.00009 +
G0101 Psme4 proteasome activator subunit 4 NM_134013 4E-87 +
G0701 Mt2a metallothionein 2A NM_005953 7E-20 -
G1201 Ggt1 gamma-glutamyltransferase 1 NM_013430 3E-46 +
G1501 Txnrd2 Thioredoxin reductase 2 NM_006440 9E-19 +
G2001 Pdia4 Disulfite Isomerase 4 NM_004911 5E-46 +
G2202 Ahcy S-adenosylhomocystein hydrolase NM_016661 1E-10 -
G2302 Cyp2f2 Cytochrome P450 2f2 NM_007817 9E-25 –
G3302 Cytb Mesocricetus auratus cytochrome b YP_003208313 9E-86 ++
4-Apoptosis
A4301 Pik3r1 phosphatidylinositol 3-kinase NM_001024955 1E-80 +
C1701 Tp53 tumor supressor p53 U07182 6E-83 -
C7103
G3701
Bcl10 B-cell CLL/lymphoma 10 NM_003921 4E-37
5E-82
+
G1503 Nfkb1 NF-B NM_008689 2E-102 +
G2201 Casp8 Caspase 8 NM_009812 6E-29 -
G2305 Eef1d Eukaryotic translation elongation factor 1 delta NM_029663 3E-17 +
G3001 Topors topoisomerase I p53-binding NM_134097 4E-10 -
G4101
G4102
Sh3kbp1 SH3-domain kinase binding protein 1 NM_031892 1E-09
0.0008
+
G5301 Cmyc myelocytomatosis oncogene AJ582076 2E-27 -
5-Lipidogenesis
A0501 Pla2g2d phospholipase A2, group IID NM_011109 0.00003 +
A3003 Dhcr7 dehydrocholesterol reductase NM_007856 3E-36 +
C0701 Scl27a1 solute carrier family 27A1 NM_198580 0.0 +
C0901 Acaa1 Acetyl-CoA acyltransferase 1 NM_130864 1E-77 +
C4602 Lpl lipoprotein lipase NM_008509 1E-37 -
G0201 Star steroidogenic acute regulatory protein NM_011485 7E-08 -
6-Protein conformation or transport
A3801 Rpn1 ribophorin I NM_133933 3E-14 -
A4701 Ergic3 ERGIC and golgi 3 NM_198398 6E-21 +
A5302 Gxylt1 glycosyltransferase 8 domain containing 3 NM_173601 0.0002 +
C0601 Ppia peptidylprolyl isomerase A NM_021130 7E-71 +
C2001 Grpel1 GrpE-like 1, mitochondrial NM_024478 1E-13 +
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mett5d1) were up-regulated. On the other hand, 7 genes
were down-regulated (CCAAT/enhancer binding protein
delta, methyl-CpG binding domain protein 1, Map
kinase 3, Protease subunit 5, SWI/SNF related actin
dependent regulator of chromatin, ATP dependent heli-
case 4 and Forkhead A3).
Xenobiotic metabolism genes such as cytochromes
and glutathione S-transferases were also found to be dif-
ferentially expressed, indicating a mobilization of cellular
Table 1 List of genes identified by Differential Display after DEHP exposure and classified by major biological func-
tion, according to GO process (Continued)
C2201 Fxn frataxin NM_008044 4E-33 +
C3602 Slc26a9 solute carrier family 26, member 9 NM_177243 1E-9 +
C7501 Slc13a3 solute carrier family 13 member 3 NM_054055 3E-29 -
G1801 Slc15a1 Solute carrier family 15 member 1 NM_053079 0.0002 -
G3702 Rpn2 ribophorin II NM_019642 3E-26 -
G6101 Nrbp1 nuclear receptor binding protein 1 NM_013392 4E-12 +
G6601 Slc6a8 solute carrier family 6 member 8 NM_005629 0.0001 -
7-Cell cycle
A0401 Ingap Mesocricetus auratus islet neogenesis associated protein U41738 4E-79 -
A3002 Cdkn2b cyclin-dependent kinase inhibitor 2B NM_004936 1E-9 -
A4801 Ppp1cc protein phosphatase 1, catalytic subunit, gamma NM_002710 2E-78 +
A5702 Sec11a SEC11 homolog A NM_014300 1E-19 +
C4002 Mapk4 mitogen-activated protein kinase 4 NM_002747 9E-26 +
C4701 Ccndbp1 cyclin D-type binding-protein 1 NM_010761 1E-17 +
C6301
C6302
Zw10 ZW10 homolog centromere/kinetochore protein NM_004724 1E-04
1E-05
-
8-Other functions
A3903 Rexo2 REX2, RNA exonuclease 2 homolog NM_015523 6E-21 -
A5403 Hk2 hexokinase 2 NM_000189 4E-28 +
A5602 Pcbp2 poly(rC)-binding protein 2 NM_031989 1E-34 +
A7301 Lyrm4 LYR motif containing 4 NM_201358 0.0004 -
C1801 Itpripl2 inositol 1,4,5-triphosphate receptor Interacting protein-like 2 NM_001033380 4E-11 +
C2401 Tsn translin NM_011650 4E-10 +
C4501 Trip4 thyroid hormone receptor interactor 4 NM_016213 0.0006 -
C7102 Tbrg3 transforming growth factor beta regulated gene 3 NR_027799 0.001 +
G0101 Psme4 proteasome activator subunit 4 NM_014614 4E-87 +
G0501 Gatad2a GATA zinc finger domain containing 2A NM_001113346 8E-15 +
G0901 Hoxa10 Homeobox A10 (HOXA10) NM_008263 1E-47 +
G1101 Iap Syrian hamster intracisternal A particle M10134 3E-73 +
G2303 Zc3h12c zinc finger CCCH type containing 12C NM_001162921 7E-9 -
G6801 Fst follistatin NM_006350 3E-42 -
Ribosomal proteins
A3703 Rpl37a ribosomal protein L37a NM_000998 0.001 +
A3901
C3901
Mrpl45 mitochondrial ribosomal protein L45 NM_025927 2E-10
6E-59
-
A3902 Rps21 ribosomal protein S21 NM_001024 7E-14 +
A4001 ./. mitochondrial 12S ribosomal RNA X84390 0.0 +
G2002 Rpl27a 60S ribosomal protein L27a NM_000990 5E-18 +
G3504 Rpl10 ribosomal protein L10 NR_026898 4E-132 +
G3601
G3602
Rpl28 ribosomal protein L28 NM_009081 3E-22
8E-180
+
G5701 Rpl22 ribosomal protein L22 NM_000983 0.00009 +
The DEHP effect is identified by (+) for 2.0-fold over-expression, (++) for 10-fold over-expression, (-) for 2.0-fold under-expression and (–) for 10.0-fold under-
expression for at least one dose of DEHP. The 37 Differential Display fragments showing no match after comparison with the RefSeq database were not listed in
the table. Id (Identification Number) represents the internal reference of the sequence used before the identification of Differential Display sequence.
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cyp1b1 and cyp2e1 was registered, whereas cyp2f2 was
found to be down-regulated. Concerning GST, the Pi
family was over-expressed while the Theta and Mu
families were down-regulated.
Differential Display results confirmed the down-regu-
lation of c-myc a n ds h o w e dd o w n - r e g u l a t i o no fp 5 3 .A
down-regulation of pro-apoptotic genes (casp8, topors...)
and an over-expression of anti-apoptotic genes (bcl10,
nfkb1, sh3kbp1...) were also observed.
Expression of genes involved in the regulation of the
cytoskeleton by qPCR
The mRNA level of the 21 genes involved in the regula-
tion of the cytoskeleton that were identified as differen-
tially expressed after 24 hrs was confirmed by qPCR.
The expression of these genes was also studied after
exposure to DEHP for 5 hrs. Out of the 21 genes, four
(coro1C, kif23, cdh3 and cttnbip1) were significantly up-
regulated by DEHP treatment after 5 hrs of exposure
(Figure 2) and one (nrp2) was significantly down-regu-
lated. A clear dose-response relationship was observed
for these 5 genes. After 24 hrs, these changes were con-
firmed for 3 genes (up-regulation of coro1C and kif23,
and down-regulation of nrp2; Figure 3). Nevertheless,
the down- and up-regulation was more pronounced
after 24 hrs than after 5 hrs of DEHP exposure, for nrp2
and kif23 respectively. For instance, in cells exposed to
50 μMo fD E H P ,Kif23 was up-regulated 17-fold at 24
hrs versus 3-fold at 5 hrs. After 24 hrs, 5 other genes
were significantlyu p - r e g u l a t e d( c o l 1 A 1 ,c r i p 1 ,c a l m l 3 ,
dclk,a n dcttnbp2) by a factor ranging from 2.0 to 4.5
with a dose-related effect (Figure 3). Eight other genes
were significantly down-regulated (thbs1, flrt2, cdh3,
has2, enah, ctnnbip1, lrrc8a and snx6), with an expres-
sion ratio between 0.2 and 0.5 (corresponding to 5 and
2 fold down-regulation respectively). All these genes
were down-regulated in a dose-dependent manner,
except for cdh3, enah, ctnnbip1, lrrc8a and snx6.A
threshold was observed with the latter genes (12.5 μM
for cdh3;5 0μMf o renah, ctnnbip1, lrrc8a and snx6).
Ctnnbip1 was significantly down-regulated only for the
lowest dose of DEHP (12.5 μM).
Although they had been identified as differentially
expressed in DD, five genes (thy1, tubb2b, b-actin, ple-
kha5 and nid2) were not shown to be significantly over-
or under-expressed by qPCR. Yet the expression profiles
of these genes indicated a dose-related increase for
Figure 2 Representative qPCR results of differentially-expressed genes involved in cytoskeleton regulation (according to the GO
process), identified by Differential Display after 5 hrs of SHE cell exposure to DEHP. These histograms show the ΔΔCt score normalized by
gapdh mRNA level. Error bars represent the standard deviation of the ΔΔCt score. Only mRNA levels showing a two-fold increase or decrease at
least, were considered indicative (*) of a change in gene expression.
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Page 7 of 17tubb2b, b-actin and pleckha5 but below the qPCR 2.0-
fold threshold. As for thy1 and nid2, the dose-related
decrease was inferior to 0.5.
Expression of apoptosis-related genes, PPARs and CYP4
genes after DEHP treatment
The expression level of bcl-2 and c-myc mRNA was
used as controls of DEHP effects. An increased level of
bcl-2 after 5 hrs of exposure and a decreased level of c-
myc after 24 hrs (Figure 4) were observed according to
qPCR, as expected.
p53 was down-regulated in a dose- and time-depen-
dent manner; a significant decrease of the mRNA level
was found after 24 hrs at 50 μM DEHP.
None of the PPAR genes was identified as being differ-
entially expressed by DD after DEHP exposure. In order
to check these results, we measured the mRNA level of
PPARa, PPAR b/δ and PPAR g, by qPCR using hamster
specific primers. No change in the expression of these
genes was observed by qPCR after 5 or 24 hrs of exposure
with DEHP in our study conditions (Figure 4). The same
verification was carried out for CYP4 genes. Neither Dif-
ferential Display nor qPCR allowed us to identify signifi-
cant expression changes compared to the control.
Discussion
The DDRT-PCR (Differential Display RT-PCR) techni-
que was used in the present study to identify the differ-
ential mRNA expression patterns between control and
DEHP-treated SHE cells. Indeed, this technique is still a
method of choice for non-sequenced or partially-
sequenced organisms and is able to identify nonabun-
dant, rare or novel transcripts [36].
Using Differential Display, we found 122 genes whose
expression was altered by DEHP treatment (79 up-regu-
lated and 43 down-regulated). The concentrations stu-
died (12.5, 25 and 50 μM) were in the range of
concentrations that induced a morphological transfor-
mation of SHE cells, i.e. concentrations up to 77 μM for
Mikalsen et al. [27] and in the range 25 μM-150 μMf o r
Cruciani et al. [29].
We measured the mRNA level of genes involved in
the regulation of the cytoskeleton using qPCR. This
focus is justified by the fact that the modifications of
cytoskeleton organization are early events in cell neo-
plastic process [37] and can be recorded in SHE cells
after 7 days of exposure to carcinogenic agents in cell
transformation assays. Morphological transformation
affects a few percentage of the mixed population of SHE
Figure 3 Representative qPCR results of differentially-expressed genes involved in cytoskeleton regulation (according to the GO
process), identified by Differential Display after 24 hrs of SHE cell exposure to DEHP. These histograms show the ΔΔCt score normalized
by gapdh mRNA level. Error bars represent the standard deviation of the ΔΔCt score. Only mRNA levels showing a two-fold increase or decrease
at least, were considered indicative (*) of a change in gene expression.
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can assume that the differentially-expressed genes mea-
sured in the first 24 hrs of exposure reflect the first tar-
gets of DEHP in the entire SHE cell population. The
transcriptomic changes which were recorded correspond
to the integrated mean of the cell responses significantly
different in the exposed populations (p < 0.01), without
consideration of cell specificity and sensitivity to DEHP.
These significant expression changes in genes involved
in cytoskeleton regulation, can be seen as early indica-
tors of disturbances that will lead to cell transformation
further in a few percentage of the most susceptible cells
of the SHE population. The role of the cytoskeleton has
been extensively studied in relation to invasion and
metastasis, but little is known of its implication in the
first stages of carcinogenesis. The identification of geno-
mic changes associated with the triggering of cell trans-
formation is useful from a mechanistic point of view
and may be valuable in screening.
Effects on cytoskeleton-related genes
DEHP was shown to affect several functions related to
the cytoskeleton. The genes involved in cytoskeleton
regulation and identified by Differential Display are
listed in table 2. To summarize, DEHP affects actin
Figure 4 Expression level of bcl-2, c-myc, p53, pi3kr1, PPARs and CYP4 family gene mRNA after treatment of SHE cells with DEHP,
using qPCR. These histograms show the ΔΔCt score normalized by the gapdh mRNA level. Error bars represent the standard deviation of the
ΔΔCt score. Only mRNA levels showing a two-fold increase or decrease at least, were considered indicative (*) of a change in the gene
expression. We observed a significant increase in the bcl-2 mRNA level after 5 hrs of exposure and a significant decrease in c-myc and p53 mRNA
levels after 24 hrs of DEHP exposition. Pi3kr1 was found to be over-expressed for both lengths of exposure. None of PPARs or CYP4 genes was
significantly over- or under-expressed after treatment.
Table 2 List of genes involved in the regulation of the
cytoskeleton and affected by DEHP
5 hrs 24 hrs
Up-regulated genes coro1C* (25 - 50 μM)
kif23* (25 - 50 μM)
cdh3* (12.5 - 25 - 50
μM)
ctnnbip1* (25 μM)
coro1C* (25 - 50 μM)
kif23* (25 - 50 μM)
col1a1* (50 μM)
crip1* (25 - 50 μM)
calml3* (12.5 - 25 - 50
μM)
dclk1* (25 - 50 μM)
cttnbp2* (50 μM)
plekha5
tubb2b
b-actin
Down-regulated
genes
nrp2* (25 - 50 μM) nrp2* (25 - 50 μM)
thbs* (50 μM)
flrt2* (50 μM)
cdh3* (12.5 - 25 - 50
μM)
has2* (50 μM)
enah* (50 μM)
lrcc8a* (50 μM)
snx6* (50 μM)
ctnnbip1* (12.5 μM)
nid2
thy1
This table summarizes the genes studied using qPCR. (*) indicates significant
effects of DEHP (2.0-fold over- or under-expression) at concentration(s)
specified in brackets. A trend for up- or down-regulation was found for the
other genes (no concentration reported).
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and cell-to-matrix adhesion processes. The expression of
genes involved in organelle transport, in cytoskeleton
remodelling, or adhesion in response to external factors
was also modified by DEHP. These results are in line
with the recent findings of Posnack et al. [38] who iden-
tified disturbances in mechanical adhesion function and
protein trafficking in rats cardiomyocytes exposed to
DEHP.
Actin polymerization and stabilization
To summarize the basic process, actin polymerization
requires the Arp2/3 complex that needs to be stabilized
by Enable Homolog (Enah) and is regulated by coronins.
Enah is involved in the dynamic reorganization of the
actin cytoskeleton, and stimulates nucleation and poly-
merization [39]. Coronins act on F-actin binding and
bundling activities, but are able to inhibit the activity of
Arp2/3 complex [40]. Actin polymers also require cor-
tactin, which stabilizes nucleation sites for actin branch-
ing and elongation [41,42]. Crip1 facilitates actin
filament bundling and stabilizes actin interaction with
a-actinin too [43]. Linkage of actin polymers to
adherens junctions, mainly composed of the transmem-
brane proteins cadherins, is insured through binding to
a-catenin and b-catenin [44].
Based on the gene expression data generated, we have
tried to synthesize the effects of DEHP on actin organi-
sation and cell adhesion specifically (Figure 5; over-
expression in red; under-expression in green). A 5- and
24-hrs exposure to DEHP over-expressed Coronin 1C
(Coro1C), resulting in F-actin disassembly [45]. Disorga-
nization was amplified by under-expression of Enah
involved in actin nucleation and polymerization, and
expression of Cttnbp2 that counteracts cortactin which
is known to stabilize the actin network. On the other
hand, the binding of actin filaments to cadherins
through catenin links appears to be reinforced owing to
under-expression of Ctnnbip1 (a b-catenin blocker) and
over-expression of Crip1, which intensifies fixation to
actinin. Globally, the effects of DEHP on actin cytoske-
leton disturb actin polymerization while intensifying
binding on actinin and catenins. Posnack et al. [38]
explored DEHP effects on rats cardiomyocytes in a
range of concentrations two and three orders of
Figure 5 Representative scheme of the genes affected by DEHP and involved in cytoskeleton regulation. Genes in red have been found
to be over-expressed using Differential Display (DD) and genes in green under-expressed. Dotted lines represent genes identified by DD but
whose expression was not significant in qPCR.
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expression of actinin, a-catenin and N-cadherin in a
concentration-dependent manner.
Cell-cell and cell-matrix adhesion
Cell-cell adhesion and cell-matrix adhesion were also
affected by DEHP treatment. The decrease in the P-
Cadherin (Cdh3) mRNA level after 24 hrs of exposure
indicates that DEHP weakened cell-cell contact, after a
transient increase at 5 hrs of exposure for all doses
tested. Weakening of cell-matrix adhesion may result
from a decrease in the Hyaluronan synthase 2 (has2)
mRNA level [46] and in Thrombospondin (Thbs1), an
adhesive protein that interacts with fibronectin, laminin,
integrins and collagen [47]. Loss of cell adhesion may
also be explained by over-expression of Coro1C because
this gene negatively regulates cell-matrix adhesion
through focal adhesion kinase (FAK)-mediated signalling
[45]. Also, under-expression of Enah, which is known to
be involved in the control of cellular adhesion by the
recruitment of proteins containing SH3- domain [48],
contributes to the loss of cell-cell adhesion.
In addition, DEHP may lessen extracellular matrix
adhesion by reducing the expression level of a number
of transmembrane proteins involved in cell-matrix con-
nections: Fibronectin leucine rich 2 (Flrt2) and Leucine
rich repeat 8A (Lrrc8a) [49], Nidogen 2, which connects
laminin-1 to the matrix [50], and Thy-1, which mediates
fibroblastic adhesion [51] and is Thbs1 expression-
dependent [52]. On the other hand, DEHP effects rein-
force the extra-cellular matrix through an over-expres-
sion of col1A1 increasing collagen. This effect may be
seen as a compensatory reaction to the weakening of
cell-to-matrix link proteins by DEHP. Sobarzo et al. [53]
demonstrated an up-regulation of N-cadherin and a-
catenin in rat testis after 2 and 7 days of DEHP treat-
ment, suggesting also a deregulation of cell adhesion
molecules in seminiferous tubules.
DEHP decreases the response to external factors,
such as the Vascular Endothelial Growth Factor
(VEGF) or the Epidermal Growth Factor (EGF)
through under-expression of neuropilin 2 (nrp2)a n d
sorting nexin 6 (snx6) respectively. Nrp2 is a mem-
brane receptor capable of binding VEGF and sema-
phorins, therefore its under-expression may inhibit cell
adhesion and migration via the loss of integrins [54].
Snx6 is able to interact with EGF receptor and Trans-
forming Growth Factor (TGF)-b receptor [55]. Under-
expression of snx6 and thbs1 may lead to decreased
interaction with Latent TGF Binding Protein (LTBP) in
the upstream of the TGF-b pathway contributing to
the repression of the TGF-b signaling pathway [56,57].
Under-expression of TGF-b is known to decrease
apoptosis in rodent hepatocytes treated with peroxi-
some proliferators (PPs) [24].
Organelle transport and cytoskeleton remodelling
DEHP also interferes with functions of microtubules
(composed of a-a n db-tubulin). Kif23, which encodes a
kinesin protein, was highly over-expressed after 5 hrs
and 24 hrs of DEHP exposure. Kif23 has been shown to
transport membranous organelles and protein com-
plexes from cell nucleus to cell periphery in a microtu-
bule- and ATP-dependent manner. Doublecortin-like
kinase (Dclk) is a microtubule-associated protein encod-
ing a Ca
2+/calmodulin-dependent kinase. Its activities
on binding and microtubule polymerization facilitate
cell motility by remodelling the microtubule cytoskele-
ton [58]. Over-expression of dclk at 24 hrs of DEHP
treatment is in line with an increased trend in b-tubulin
(tubb2b).
Calmoduline-like 3 (calml3) was over-expressed after
24 hrs of DEHP exposure. Calmodulin (CaM) is a cal-
cium-binding protein that translates the Ca
2+ signal into
a wide variety of cellular processes, including the regula-
tion of cytoskeleton remodelling acting with Caldesmon
[59] or with Wnt pathway [60]. Calml3 is a CaM family
member protein which increases cell motility by stabiliz-
ing and increasing myosin-10 for cell migration [61].
Other genes involved in signal transduction pathways and
cytoskeleton regulation
We measured an over-expression level of phosphatidyli-
nositol 3-kinase r1 (pi3kr1) using Differential Display
and qPCR. Pi3k is a key signalling molecule in the PIP3
signalling transduction pathway and in actin reorganiza-
tion and cell adhesion [62] and is able to regulate the
synthesis of collagen I [63]. An activation of PI3K is also
associated with a phosphorylation-dependent activation
of Akt which contributes to tumorigenesis and metasta-
sis [39]. The over-expression of pi3kr1 can be related to
the under-expression of ctnnbip1 which interacts with
b-catenin. In addition to the function of b-catenin in
the actin cytoskeleton, its role in the regulation of Akt
pathway activation [64] or in Wnt pathway regulation
[65] is advanced. This protein forms part of a complex
that captures growth and proliferation signals from the
cell surface and is then activated to stimulate the
expression of genes involved in cell proliferation. It
would be worth studying b-catenin-dependent transcrip-
tion in relation to carcinogenicity.
DEHP effects in the SHE model compared to rats and
mice
While the expression of cyp1b1 and cyp2e1 was up-
regulated and cyp2f2 under-expressed, no change in
expression level of CYP4 genes was found using DD and
qPCR after DEHP exposure in our experimental condi-
tions. CYP4 genes are said to be involved in peroxisome
proliferation [66]. Eveillard et al. [67] who studied the
involvement of DEHP in lipidogenesis in rats, found a
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exposure to DEHP (200 mg/kg.day). They registered a
significant increase in CYP4 levels after 14 days [68] and
after 21 days [67] of exposure. On the other hand, we
found no increased mRNA level of CYP4 and PPAR
genes in DEHP-treated SHE cells. This underlines that
the genes expression changes noted in the present study
are independent of PPARs induction. Eveillard et al. [67]
found that induced expression of cyp2b10 by DEHP was
also independent of PPARa induction but CAR depen-
dent. No change in CAR expression was registered in
SHE cells, which may explain why no change in cyp2b10
was noted. Our results are consistent with the study of
Ren et al. [20] who identified DEHP regulated genes
independent of PPARa and CAR in rats and mice.
In our study, lipogenesis and xenobiotic metabolism
pathways were impacted by DEHP, but not in a major
prior way. This may be explained by the lower sensitivity
of the hamster model compared with rats and mice to
peroxisome proliferators [69]. Indeed, the Syrian hamster
model presents an intermediate response between rats or
mice and humans who are known to be non-responsive
to PP induction [24]. The hamster model, like humans, is
less responsive to PP induction than rats and mice, which
is an advantage for mechanistic studies of PP effects and
for screening human chemical carcinogens.
On the other hand, three genes (Actin b, Lipoprotein
lipase, and Acetyl-Coenzyme A acyltransferase 1a) and 5
gene isoforms (Glutathione S-transferase-pi, -mu, -theta,
CCAAT/enhancer binding protein and Nuclear receptor
s u b f a m i l y1 )w e r ec o m m o n l yf o u n di no u rs t u d ya n d
those carried out by Eveillard et al. [67,68], suggesting a
pattern of response specific to DEHP.
Takashima et al. [70] also found similar responses in
DEHP-treated mice. Up-regulation of rab1b,aR A S
oncogene family member involved in cellular signal
transduction or survival, was found in the latter study
and in the present one. b-Tubulin was clearly over-
expressed in mice, a trend which was noted in our
study. Some gene isoforms of cadherin, nidogen, cyp1
family genes or LIM domain were also impacted in the
liver of mice exposed to DEHP [70].
DEHP effects on transcription factors
Other genes identified by Differential Display and
involved in transcription and signal transduction path-
ways or apoptosis were also targeted by DEHP. A signif-
icant under-expression of p53 was found after 24 hrs of
DEHP exposure using Differential Display and qPCR.
This under-expression is in line with the anti- apoptotic
effects of DEHP.
We confirmed the over-expression of bcl-2 after 5 hrs
and the under-expression of c-myc after 24 hrs, events
reported in a previous study on DEHP treated SHE cells
in conditions similar to the present ones [26]. Map
Kinases such as Mapk3, Mapk4 and Mapk15 were tar-
geted by DEHP. Further investigations of Map Kinase
pathways could be relevant due to their involvement in
activities of transcription factors.
The G protein-coupled estrogen receptor (gper)w a s
found to be over-expressed in Differential Display. Gper
can be activated by estrogen-like compounds and its
effect on cytoskeleton architecture has been reported
[71]. Because of its implication in the regulation of
MAPK [72] or TGF-b pathways [73], it would be worth-
while to investigate gper further.
Performances of DD
The confirmation of differentially-expressed genes by
qPCR showed that the expression levels of more than
75% of genes identified by DD were confirmed by qPCR.
A comparative table of the sensitivity of DD versus qPCR
is given in additional file 1. qPCR is more likely to quan-
tify subtle changes in the expression level of mRNAs at
different concentrations while DD seems to be more sen-
sitive but is less discriminating. To summarize, 35% of
the genes identified as differentially expressed in DD gave
the same response at the same DEHP concentrations
with qPCR while 40% were detected by DD at a lower
DEHP concentration than with qPCR.
Conclusion
Transcriptional responses of SHE cells to DEHP were stu-
died in conditions inducing the cell neoplastic transforma-
tion, in order to identify gene expression changes in
relation with effects of this non-genotoxic carcinogen.
Functions impacted by DEHP were found to be PPAR-
independent. Effects on cytoskeleton related genes indi-
cated disturbances on actin polymerization and stabiliza-
tion, cell-cell and cell-matrix adhesion and protein
trafficking.
This is the first study that elucidates the genomic
changes of DEHP on the organization of the cytoskele-
ton. Whether the expression changes of cytoskeleton-
related genes identified here such as coro1C, nrp2, kif23,
are specific to DEHP or to cell transforming agents more
generally would require further studies. To answer, the
gene sets identified as significantly over- or under-
expressed in this study must be explored on other non-
genotoxic carcinogens to identify biomarkers predictive
of early events in the multistep carcinogenic process.
Early disturbances in the expression of cytoskeleton-
related genes should be considered good candidates.
Methods
Chemicals
DEHP (C.A.S. No. 117-81-7, purity 99%), purchased
from Aldrich Chemicals (Gillingham, England) was
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The latter was obtained from Sigma Aldrich (St Quentin
Fallavier, France) and was used at a final concentration
of 0.1%.
Nucleic acid stain Gelred purchased from Interchim
(Montluçon, France) was used at a final concentration
of 1:10000 (v/v).
All chemicals used for this study were electrophoresis
grade or molecular biology grade. Their origin is speci-
fied in the following sections.
SHE cell culture and treatment
SHE cells were isolated from Syrian hamster embryos at
day 13 of gestation using the procedure described by
Pienta et al. [74] and in accordance with the modifica-
tions suggested by Elias et al. [75]. Differentiated tissues,
such as eyes, heart and viscera were removed and the
remaining tissues were dissociated by dispase (1.2 U/
ml). Stock cells were preserved in liquid nitrogen.
After thawing, passage-2 primary cells were pre-cul-
tured until they reached 80% confluency. The culture
medium was Dulbecco’s modified Eagle medium
(DMEM) (Gibco, Invitrogen, Cergy Pontoise, France)
supplemented with 10% foetal calf serum (FCS)
(Hyclone, Brebières, France; lot N°#ASB28835), 1.5 g/L
NaHCO3 at 37°C in a 10% CO2 humidified atmosphere
and pH 7.0. No phenol red was added to the medium.
Cells used for the DEHP studies were sampled from a
monolayer during the growing phase, 48 hrs after seed-
ing. Cells were trypsinized and treated during replating
with DEHP at concentrations of 0 μM( v e h i c l ec o n t r o l ) ,
12.5 μM, 25 μMa n d5 0μM in DMEM culture medium
supplemented with 10% FCS. Cells were then incubated
for 5 hrs and 24 hrs at 37°C in a 10% CO2 humidified
atmosphere.
RNA isolation
Total RNA extractions were performed directly in the
dish, using Nucleospin RNA II Extract Kit (Macherey
Nagel, Hoerdt, France), according to the manufacturer’s
instructions. A DNAse I treatment was performed
directly through the column used to collect RNAs and
before the elution phase of DNA-free RNA.
RNA was quantified by spectrophotometry (Nanodrop,
Labtech) measuring the A260/A280 ratio and its quality
was ensured by electrophoresis using a 1% RNase-free
agarose gel. Aliquots were stored at -80°C before use for
Differential Display and Real-time PCR.
Anchored Reverse transcription (RT) and Differential
Display
The Differential Display was performed as described by
Liang et al. [35], with minor modifications concerning
DD fragment revelation with GelRed.
For Differential Display, three separate RT reactions
were performed with a different one-base anchored
oligo-dT primer (H-dTA, H-dTC and H-dTG) to pro-
duce three different subsets of cDNA pools. The
sequences of the anchored and the arbitrary primers are
given as additional file 2. The RT reactions were carried
out using 2 μL of each primer (50 μM) and 4 μg of total
RNA. 8 μL of RevertAid M-MuLV Reverse Transcrip-
tase 5x reaction buffer (Fermentas, Saint-Rémy-lès-
Chevreuse, France), 1.5 μL of 10 mM dNTPs (Fermen-
tas, Saint-Rémy-lès-Chevreuse, France) and up to 35 μL
Nuclease-free water were added to each tube, mixed,
then heated at 70°C for 3 min. Tubes were centrifuged
and incubated on ice for 5 min, then 2 μL( 4 0U )o f
RNaseOUT Recombinant RNase Inhibitor (Invitrogen,
Cergy Pontoise, France), 1 μL( 2 0 0U )o fR e v e r t A i dM -
MuLV RT (Fermentas, Saint-Rémy-lès-Chevreuse,
France) and 2 μL of Nuclease-free water were added to
each tube. Each tube was mixed by gentle pipetting then
incubated in a thermocycler at 42°C for 1 h, followed by
95°C for 10 min. The tubes were then centrifuged and
stored at -80°C until use.
Amplification was then performed using combinations
of the three original anchored primers from the reverse
transcription step and eighty arbitrary 13-mers (H-AP),
giving a total of 240 amplification combinations. All
reactions contained 2 μL of a 10x PCR buffer containing
25 mM of MgCl2,1 . 6μLo f1m Md N T Pm i x ,1Uo f
Taq Polymerase (Euromedex, Souffelweyersheim,
France) and the primer combination at a final concen-
tration of 1 μM. Tubes were incubated for 5 min at 95°
C. The next 40 cycles were 95°C for 30 s (denaturation),
40°C for 2 min (annealing), 72°C for 1 min (amplifica-
tion). A final extension of 72°C for 10 min completed
the cycle.
After thermocycling, PCR-amplified fragments were
resolved in a 6% native polyacrylamide gel in 1 × TBE
buffer (89 mM Tris base/89 mM boric acid/2 mM
EDTA, pH 8.0), using 10 μL of PCR product mixed with
2 μl of loading buffer (0.05% xylene cyanol, 40% sucrose,
20 mM EDTA, pH 8.0). Gels were run at 100 V for 20
hrs, then the fragments were stained with GelRed 1X in
water, for 30 min in the dark. Bands on the gel were
revealed on a UV-transluminator. PCR products that
showed differential expression between control and trea-
ted samples were identified with QuantityOne
® 1-D
analysis software (BioRad, Marne-la-Coquette, France).
Bands which were up- or down- regulated more than
2-fold, were selected and characterized in the next step
of analysis. Differentially-expressed bands were excised,
reamplified and their sizes were checked before cloning.
To summarize, fragments of interest were recovered
using a clean razor blade and extracted from the gel
matrix by boiling in 200 μL of buffer (10 mM Tris/1
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Genes Accession N° Primers sequence (5’-3’)
Housekeeping gene
gapdh Glyceraldehyde 3-phosphate dehydrogenase DQ403055 F: CAATGACCCCTTCATTGACC
R: GACAAGCTTCCCGTTCTCAG
Regulation of cytoskeleton
tubb2b b-Tubulin NM_023716 F: GCAACATGAATGACCTGGTG
R: ACCAGAGACCCAGCACAAAC
thy1 Thy1 Antigen NM_009382.3 F: AAGGCCTCTGCCTGTAGTGA
R: GAAGAGGCAGGTTGCAAGAC
actin b-Actin NM_007393 F: CACCACCACAGCCGAGAG
R: CCAGGGAGGAAGAGGATGC
col1a1 Collagen a1 NM_000088 F: GGGTCATTTCCACATGCTTT
R: TCCGGGTTTCAGAGTACCAC
thbs1 Thrombospondin 1 NM_011580 F: CCAAAGCCTGCAAGAAAGAC
R: CCTGCTTGTTGCAAACTTGA
plekha5 Plekstrin homology A5 NM_019012 F: GTGCATCTGCCTGAAGACAA
R: TGGGAACCTTTAACGACTGG
kif23 Kinesin 23 NM_024245.4 F: CCTGAGCTTTCCTGACCAAG
R: AGTTCCTTCTGGGTGGTGTG
has2 Hyaluronan synthase 2 NM_008216 F: CGGAGGACGAGTCTATGAGC
R: TTTTCCGGTGTTCCAAAAAG
flrt2 Fibronectin leucine rich 2 NM_201518 F: ACCGCACTGTGGAAGATACC
R: GCAAGACAACGAGCACAAAA
enah Enabled homolog NM_008680 F: GCCTATGCTTCAGCACTTCC
R: GGGCGATTGTCTTCTGACAT
dclk1 Doublecortin like 1 NM_019978 F: AGCCTCCACCAGCTCAGTTA
R: CCATACACATCGCTCCATTG
ctnnbip1 Catenin b interacting protein 1 NM_020248 F: TTGGCTGCAGAAAGAAACCT
R: CCAGCCAATCACAACCTTTT
crip1 Cystein rich protein NM_007763 F: AGTCCAGAGCCTGCAACCTA
R: GGAGTAGCAGGGATGATTGC
coro1c Coronin NM_014325 F: GCAGAAGAGTGGTTCGAAGG
R: TGATCAGGTCGCACTTCTTG
cdh3 Cadherin 3 NM_007665 F: CACACGACCTCATGTTCACC
R: CTGTACCTCATGGCCCACTT
calml3 Calmodulin like 3 NM_027416.3 F: ATCGACAAGGATGGAAACG
R: ATCTACCTCCTCGTCGCTCA
cttnbp2 Cortactin binding protein 2 NM_030249 F: GACAAAGAAGGCTGGACTGC
R: CTCACCCACGGAAATCCTTA
lrrc8a Leucine rich repeat 8A NM_177725 F: AGAGCCCACTTACCCCAACT
R: GTGTGCAGAAGCACGAGGTA
snx6 Sorting nexin 6 NM_021249 F: CCAAGACCTGATTTTGATGCTTC
R: CATGCATCGCAACTGTCTTC
nrp2 Neuropilin 2 NM_0010774 F: ATAAGCACTGATGTCCCACTG
R: GAGTTGCTCCAATCTCCTTCA
nid2 Nidogen 2 NM_008695 F: CTCATTCAGTTGTGCCTGC
R: ATAGCTGCCTCATGACATCG
Regulation of apoptosis
pi3kr1 phosphatidylinositol 3-kinase (p85a) NM_001077495 F: CGAGCCCGACCGGAGGTGAA
R: CGCACACTGCCGTCCGAGTT
bcl-2 B-cell lymphoma 2 AJ582074 F: CGCAGAGATGTCCAGTCAGC
R: CGAACTCAAAGAAGACCACAA
c-myc cellular myelocytomatosis oncogene AJ582076 F: GACCCTGATTCGGACCTCTT
R: CGACTCCACAGCCTTCTCTC
p53 tumor supressor p53 U07182 F: ATGACGGAAGTTGTAAGAC
R: TCGGATAAGATGCTGAGG
PPARs genes
ppar a peroxisome proliferator activated receptor alpha AY170844 F: GTTTCTTTCGGCGAACTATT
R: ACACGTGAGAATCTCTGCTT
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overnight precipitation at -80°C, the eluted DNA was
reamplified using the same primers and PCR conditions
as the ones used in the DD-PCR step. Reamplified DNA
was run in a 1.5% agarose gel containing 1X GelRed
and recovered using NucleoSpin
® Extract II kit
(Macherey Nagel, Hoerdt, France) before cloning.
Cloning was carried out using a TA Cloning Kit
(pGEM-T, Promega, Charbonnières, France), according
to the manufacturer’s instructions. Plasmid DNA was
extracted from the cultures using Nucleospin
® Plasmid
QuickPure (Macherey Nagel, Hoerdt, France), according
to the manufacturer’s instructions and sequenced bidir-
ectionally by the DNA sequencing service of MWG
Operon (Ebersberg, Germany), using T7 and SP6
primers.
Identification of differentially-expressed genes
Sequences were compared with the National Centre of
Biotechnology Information Gene Bank database (http://
www.ncbi.nlm.nih.gov) using the tBLASTx algorithm
and RefSeq mouse or Refseq human as a reference.
Confirmation of differentially-expressed sequences by
Quantitative Real Time PCR (qPCR)
First-strand cDNA was synthesized from 2 μgo ft o t a l
RNA using VILO-Superscript™ III reverse transcriptase
(Invitrogen, Cergy Pontoise, France) and random-hex-
amer primers. To summarize, 2 μgo ft o t a lR N Aw a s
combined with 4 μLo f5 XV I L O ™ reaction mix (con-
taining RT buffer, MgCl2, dNTPs and random primers)
and 2 μL of 10X enzyme mix (containing Superscript
®
III and RNase inhinitor). The final volume was adjusted
to 20 μL and the reaction mix was incubated at 42°C for
60 min. Then, cDNAs were diluted 20-fold, according to
the manufacturer’s instructions, before qPCR amplifica-
tions. The oligonucleotides used as primers in the quan-
titative real time PCR assay are described in table 3. If
possible, at least one primer in each pair spanned an
exon-intron boundary. PCR was carried out using Fast
SYBR
®Green Master Mix (Applied Biosystem,
Courtaboeuf, France). Amplifications were performed on
a StepOnePlus Real-Time PCR system (Applied Biosys-
tem, Courtaboeuf, France). Each qPCR reaction con-
tained 10 μL of 2X Fast SYBR
®Green Master Mix, 5 μL
of primers, 2 μL of diluted cDNA and 3 μL of Nuclease-
free water. Amplification parameters were set as follows:
initial denaturation (95°C, 3 min), and then amplifica-
tion (95°C, 3 s and 60°C 30s) for 40 cycles. Glyceralde-
hyde 3-phosphate dehydrogenase (gapdh) mRNA level
was used as a housekeeping gene to normalize qPCR
data. This gene was chosen because DEHP exposure did
not affect its expression unlike b-actin which was also
tested (data not shown). qPCR results were analyzed
using the software provided with the thermocycler and
DataAssist, using the ΔΔCt method [76]. Each validated
primer pair used yielded a single peak of dissociation on
the melting curve. The efficiency calculated by standard
curve with five log-10 dilution points was between 0.95
and 1.05. A 2.0-fold threshold and a p-value of 0.05
were used to determine the significance of differential
expression levels according to the standard parameters
of DataAssist.
Additional material
Additional file 1: Comparative table of the sensitivity of DD versus
qPCR. Comparisons between the ratio of bands intensity compared to
the control on the gel using an image analysis software (QuantityOne
®®
1-D analysis software BioRad, Marne-la-Coquette, France) for Differential
Display and the ΔΔCt score normalized by gapdh mRNA level after
analysis with StepOne and DataAssist (Roche Applied Biosystem,
Courtaboeuf, France) for qPCR.
Additional file 2: Primers for Differential Display. List of the
sequences of the anchored and the arbitrary primers used for the
Differential Display experiments.
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Table 3 List of the primers used for real-time qPCR (Continued)
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cyp4a17 Cytochrome P450 4A17 AJ555628 F: ACCAGATGCCCTACACTACC
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cyp4a18 Cytochrome P450 4A18 AJ555629 F: ACCAGATGCCCTACACTACC
R: GGCCATAAATGGAGATTGCA
cyp4a19 Cytochrome P450 4A19 AJ555630 F: ACCAGATGCCCTACACTACC
R: GTGCATAAATGGAGAGTGTG
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